Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease.

Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez OL, Tudorascu DL, Villemagne VL, Ikonomovic MD, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Aizenstein HJ, Klunk WE, Snitz BE, Maki P, Thurston RC, Cohen AD, Ganguli M, Karikari TK, Rosa-Neto P, Pascoal TA. · 2023

Read Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease. by Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez OL, Tudorascu DL, Villemagne VL, Ikonomovic MD, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Aizenstein HJ, Klunk WE, Snitz BE, Maki P, Thurston RC, Cohen AD, Ganguli M, Karikari TK, Rosa-Neto P, Pascoal TA. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10353939.txt.

Introduction

Bellaver and a large team asked in 2023 why some brains with amyloid do not go on to form tau tangles. Amyloid and tau are the two hallmark proteins of Alzheimer's disease. Some people carry amyloid yet stay sharp and show no tau harm. Astrocytes are star-shaped support cells in the brain that can switch to an active state.

Bellaver studied 1,016 people across three groups who had no memory loss. Amyloid linked to raised tau in blood only in people whose astrocytes were active. Brain scans showed the same split for tau growth over time. The finding puts active astrocytes early in the chain of the disease. It may help pick the right people for early drug trials.

Catalog record

CREATORBellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez OL, Tudorascu DL, Villemagne VL, Ikonomovic MD, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Aizenstein HJ, Klunk WE, Snitz BE, Maki P, Thurston RC, Cohen AD, Ganguli M, Karikari TK, Rosa-Neto P, Pascoal TA.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10353939

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease By Bruna Bellaver, Guilherme Povala, Pamela C. L. Ferreira, João Pedro Ferrari-Souza, Douglas T. Leffa, Firoza Z. Lussier, Andréa L. Benedet, Nicholas J. Ashton, Gallen Triana-Baltzer, Hartmuth C. Kolb, Cécile Tissot, Joseph Therriault Published in: Nature Medicine DOI: 10.1038/s41591-023-02380-x ABSTRACT An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation. Here, in a biomarker study across three cohorts (n = 1,016), we tested whether astrocyte reactivity modulates the association of Aβ with tau phosphorylation in CU individuals. We found that Aβ was associated with increased plasma phosphorylated tau only in individuals positive for astrocyte reactivity (Ast+). Cross-sectional and longitudinal tau–positron emission tomography analyses revealed an AD-like pattern of tau tangle accumulation as a function of Aβ only in CU Ast+ individuals. Our findings suggest astrocyte reactivity as an important upstream event linking Aβ with initial tau pathology, which may have implications for the biological definition of preclinical AD and for selecting CU individuals for clinical trials. MAIN Rapid advances in fluid and neuroimaging biomarkers have facilitated the understanding of the dynamic associations between Alzheimer’s disease (AD)-related pathophysiological processes in the living human brain. These biomarker studies suggest that brain accumulation of amyloid-β (Aβ) precedes tau pathology in cognitively unimpaired (CU) individuals1–3, which is closely related to the development of cognitive symptoms4–6. However, the reasons why Aβ pathology is not associated with AD-related progression in some CU individuals is one of the most pressing questions in the field7–9. In addition to revealing key biological players associated with disease progression, finding predictive markers of early Aβ-related tau pathology would allow for the identification of CU individuals who are more likely to develop AD even before the first signs of pathological tau, facilitating enrollment in early prevention clinical trials10. The fact that Aβ leads to tau pathology in some individuals, but not in others, suggests the presence of other biological processes capable of triggering the deleterious effects of Aβ in the early disease stages. Postmortem studies show that astrocyte reactivity is a common neuropathological finding in CU individuals and, like cortical Aβ plaques, one of the earliest abnormalities in AD11–15. Experimental literature suggests that astrocyte reactivity is critical for triggering Aβ-induced tau phosphorylation16 and that the attenuation of astrocyte reactivity mitigates tau pathology17,18. Additionally, glial fibrillary acidic protein (GFAP)-positive astrocytes can internalize tau and may contribute to its propagation19,20. Altogether, these experimental results support a close link between Aβ, astrocyte reactivity and tau. Clinical studies support that plasma measures of GFAP correlate with its CSF levels and are increased in CU individuals with AD pathophysiology, representing a robust proxy of astrocyte reactivity in the brains of these individuals21–24. Based on this previous literature, we designed a multisite biomarker study including three cohorts to test the hypothesis that the presence of astrocyte reactivity biomarker abnormality is a key element in determining the association of Aβ burden with early tau phosphorylation and aggregation biomarkers in preclinical AD. RESULTS Participants We investigated 1,016 CU individuals (mean age = 69.6 ± 8.9, clinical dementia rating (CDR) = 0) from two research (Translational Biomarkers in Aging and Dementia (TRIAD), McGill University, Canada and Pittsburgh, University of Pittsburgh, USA) and one population-based (Monongahela-Youghiogheny Healthy Aging Team (MYHAT), Pittsburgh, USA) cohorts with in vivo biomarkers. Individuals were classified as negative (Ast−) or positive (Ast+) for astrocyte reactivity based on their plasma GFAP levels. Demographic and clinical characteristics of participants are summarized in Table 1. Overall, participants classified as Aβ+/Ast+ presented increased plasma phosphorylated tau (p-tau)181, p-tau231 and p-tau217 compared to other groups. No differences in Aβ levels were observed between CU Aβ+/Ast− and Aβ+/Ast+ in any cohort. Demographic characteristics of individuals segregated by cohort are presented in Supplementary Tables 1–3.Table 1Demographics and key characteristics of participantsCharacteristicsAβ−/Ast− (n = 557)Aβ−/Ast+ (n = 165)Aβ+/Ast− (n = 186)Aβ+/Ast+ (n = 108)Age, mean (s.d.)68.2 (8.6)72.1 (8.2)a68.6 (7.6)b74.7 (10.6)a,cSex, n (% female)367 (65.9)137 (83.0)a122 (65.6)b79 (73.1)MMSE/MoCA, mean (s.d.)28.1 (3.3)/27.5 (1.8)28.1 (3.2)/28.1 (1.7)27.8 (3.2)/26.7 (4.1)b27.1 (6.1)/27.2 (1.4)APOE ε4 (% of carriers)89 (16.0)25 (15.2)33 (17.7)25 (23.1)Education, years (s.d.)15.0 (2.7)15.2 (3.1)14.8 (2.7)15.0 (2.8)Aβ burden (z score, s.d.)−0.52 (0.65)−0.40 (0.57)1.17 (0.63)a,b1.25 (0.69)a,bPlasma GFAP (z score, s.d.)−0.50 (0.51)1.20 (0.75)a−0.42 (0.52)b1.48 (0.88)a,b,cPlasma p-tau181 (z score, s.d.)−0.12 (0.90)0.10 (0.82)a−0.14 (0.97)0.77 (1.89)a,b,cPlasma p-tau231 (z score, s.d.)−0.03 (1.00)−0.12 (0.82)−0.04 (0.86)0.55 (1.26)a,b,cPlasma p-tau217 (z score, s.d.)−0.27 (0.38)−0.24 (0.38)0.17 (0.49)1.12 (1.99)a,b,cPlasma neurofilament light (z score, s.d.)−0.24 (0.62)0.42 (0.99)a−0.13 (1.22)b0.80 (1.47)a,b,cMissing APOE ε4: 140 Aβ−/Ast−, 43 A−/Ast+, 45 Aβ+/Ast− and 17 Aβ+/Ast+. Missing neurofilament light: 2 Aβ−/Ast−, 2 Aβ−/Ast+ and 1 Aβ+/Ast−. Plasma p-tau231 is available for a subset of participants from TRIAD and Pittsburgh cohorts. Plasma p-tau217 is available for a subset of participants from the TRIAD cohort.aDifferent from Aβ−/Ast−.bDifferent from Aβ−/Ast+.cDifferent from Aβ+/Ast−. Astrocyte reactivity affects Aβ-dependent tau phosphorylation We z scored biomarker levels inside each cohort and applied a robust linear regression to model the trajectory of plasma p-tau181, the only p-tau biomarker available in all cohorts, as a function of Aβ burden (plasma or positron emission tomography (PET)) in CU individuals classified as Ast− (n = 743) or Ast+ (n = 273). Notably, we observed that plasma p-tau181 levels increased as a function of Aβ only in CU Ast+ individuals (Fig. 1a). Similarly, linear regression showed a significant association between Aβ burden and plasma p-tau181 in CU Ast+ (β = 0.34, t = 5.37, P < 0.0001; Fig. 1b and Extended Data Table 1) but not in CU Ast− (β = 0.04, t = 1.06, P = 0.29; Fig. 1b) individuals. A significant interaction between Aβ burden and astrocyte reactivity status on plasma p-tau181 (β = 0.31, t = 4.62, P < 0.0001; Fig. 1b) further supported that the presence of astrocyte reactivity was key to determining Aβ effects on tau phosphorylation. These results were replicated using different cutoff values to determine reactive astrocyte positivity (Extended Data Table 2). In addition, linear regression using only continuous values for Aβ, p-tau181 and GFAP levels confirmed that these results were not driven by biomarker thresholds (β = 0.10, t = 3.22, P = 0.0013; Fig. 1c). Cohen’s d analysis revealed that the presence of both Aβ+ and Ast+ has a large magnitude of effect on tau phosphorylation (Cohen’s d = 0.80), whereas Aβ+ in the absence of Ast+ presented a negligible effect size (Fig. 1d). Voxel-wise analysis confirmed that Aβ levels associated with plasma p-tau181 only in the presence of astrocyte reactivity in some brain regions previously shown to present early Aβ pathology in PET studies, including the posterior cingulate, precuneus and insula25 (Fig. 1e).Fig. 1Astrocyte reactivity influences Aβ-dependent tau phosphorylation.a, Robust linear regressions show that plasma p-tau181 increases as a function of Aβ burden only in the presence of astrocyte reactivity (Ast+) in all cohorts together (n = 1,016). b, Linear regressions adjusted for age and sex revealed an interaction between Aβ burden and astrocyte reactivity status on p-tau181 levels in all cohorts (n = 1,016). Shaded areas represent 95% confidence intervals of the regression lines. c, Continuous association between Aβ pathology, plasma p-tau181

Read the complete text